司普奇拜单抗治疗中重度季节性过敏性鼻炎:一项随机3期试验
这项3期多中心随机双盲安慰剂对照试验纳入108例基线血嗜酸性粒细胞≥300个/μl的中重度季节性过敏性鼻炎成人患者,按1:1随机接受司普奇拜单抗皮下注射(600 mg负荷剂量后300 mg,每2周一次,共4周)或安慰剂。结果显示司普奇拜单抗在2周和4周时较安慰剂显著改善鼻部症状总分,并显著改善多个次要终点,治疗中出现的不良事件两组相当。
要点
- 司普奇拜单抗2周时rTNSS较基线变化的最小二乘均差为-1.3(95%CI -2.0至-0.6,P=0.0008),4周时为-1.7(95%CI -2.5至-0.8,P=0.0002)。
- 司普奇拜单抗显著改善了经多重检验的次要终点,包括眼部症状评分和生活质量评分。
- 治疗中出现的不良事件在司普奇拜单抗组与安慰剂组之间相当。
核心结论
- 花粉季节给予司普奇拜单抗可改善中重度季节性过敏性鼻炎患者的鼻部和眼部症状及生活质量。
研究设计与样本
- 3期多中心、随机、双盲、安慰剂对照临床试验,纳入108例诊断为中重度季节性过敏性鼻炎且基线血嗜酸性粒细胞计数≥300个/μl的患者。
- 参与者按1:1随机接受司普奇拜单抗皮下注射(600 mg负荷剂量后300 mg,每2周一次,共4周)或安慰剂。
- 主要终点为前2周每日回顾性鼻部症状总分(rTNSS)较基线的平均变化。
主要发现
- 2周时每日rTNSS较基线变化的最小二乘均差为-1.3(95%CI -2.0至-0.6,P=0.0008),4周时为-1.7(95%CI -2.5至-0.8,P=0.0002)。
- 司普奇拜单抗显著改善了经多重检验的次要终点,包括4周rTNSS、2周和4周的回顾性眼部症状总分及鼻结膜炎生活质量问卷评分。
- 治疗中出现的不良事件在两组间相当。
- 药效学和探索性分析提示,花粉季节观察到的结局改善可能归因于司普奇拜单抗治疗对2型炎症的减轻。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Seasonal allergic rhinitis (SAR) places a significant socioeconomic burden, particularly on individuals with poorly managed recurrent and severe symptoms despite standard-of-care treatment. Stapokibart, a humanized monoclonal antibody that targets the interleukin (IL)-4 receptor subunit alpha, inhibits its interaction with both IL-4 and IL-13 in type 2 inflammation. Here we aim to assess the efficacy and safety of stapokibart as an add-on therapy in adults with moderate-to-severe SAR. The study was a phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial with 108 patients diagnosed with moderate-to-severe SAR and having baseline blood eosinophil counts ≥300 cells μl-1. Participants were randomized (1:1) to receive 600 mg (loading dose) to 300 mg stapokibart subcutaneously or a placebo every 2 weeks for 4 weeks. The primary endpoint was mean change from baseline in daily reflective total nasal symptom score (rTNSS) over the first 2 weeks. Multiplicity-tested secondary endpoints included changes in rTNSS over 4 weeks, reflective total ocular symptom score and Rhinoconjunctivitis Quality of Life Questionnaire score over 2 weeks and 4 weeks. Compared with the placebo, stapokibart led to a significant improvement in the mean change from baseline in daily rTNSS during the 2-week (least-squares mean difference, -1.3; 95% confidence interval, -2.0 to -0.6; P = 0.0008) and 4-week (least-squares mean difference, -1.7; 95% confidence interval, -2.5 to -0.8; P = 0.0002) treatments. Stapokibart significantly improved the multiplicity-tested secondary endpoints. Treatment-emergent adverse events were comparable between the groups. Pharmacodynamics and exploratory analyses indicated that the observed improvements in outcomes during pollen season may be attributed to the reduction of type 2 inflammation in response to stapokibart treatment. The results of this trial show that pollen seasonal administration of stapokibart improved both nasal and ocular symptoms and quality of life in patients with moderate-to-severe SAR. ClinicalTrials.gov registration: NCT05908032 .
引用
- Zhang Y, Li J, Wang M, et al. Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial. Nat Med. 2025. PMID: 40186079. doi:10.1038/s41591-025-03651-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。